UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000030937 |
|---|---|
| Receipt number | R000035288 |
| Scientific Title | Efficacy and applicability of respiratory muscle training on the balance of inspiratory-to-expiratory muscle strength and breathing timing in patients with chronic obstructive pulmonary disease: a preparatory research study |
| Date of disclosure of the study information | 2018/02/01 |
| Last modified on | 2022/01/25 11:43:31 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Efficacy and applicability of respiratory muscle training on the balance of inspiratory-to-expiratory muscle strength and breathing timing in patients with chronic obstructive pulmonary disease: a preparatory research study
Acronym
Efficacy of respiratory muscle training for breathing timing in chronic obstructive pulmonary disease
Scientific Title
Efficacy and applicability of respiratory muscle training on the balance of inspiratory-to-expiratory muscle strength and breathing timing in patients with chronic obstructive pulmonary disease: a preparatory research study
Scientific Title:Acronym
Efficacy of respiratory muscle training for breathing timing in chronic obstructive pulmonary disease
Region
| Japan |
Condition
Condition
Chronic obstructive pulmonary disease (COPD)
Classification by specialty
| Pneumology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
In this clinical trial, chronic obstructive pulmonary disease (COPD) patients will receive either three months of inspiratory or expiratory muscle training according to the pattern of resting/exertional breathing timing. In parallel with the training, nutrition treatment with medium-chain triglycerides (MCT) will also be given. The purpose of the present study was to determine the effect of training and treatment on the changes in balance between inspiratory and expiratory muscle strength and, subsequently, on the pattern of exertional breathing timing. We will also evaluate the benefits of these changes in exertional breathing timing, if any, on exercise tolerance in COPD patients.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Exertional changes in breathing timing (Ti/Ttot)
Key secondary outcomes
1.Symptom (CAT score, SGRQ score)
2.Body weight, Body Mass Index
3.Respiratory function (FEV1, %FEV1, FEV1%, VC, and %VC)
4.Forced oscillation technique (resistance and reactance)
5.The following parameters in cardiopulmonary exercise testing (CPET): minute ventilation (VE), oxygen uptake (VO2), carbon dioxide output (VCO2), breathing frequency (fR), tidal volume (VT), physiologic dead space/tidal volume ratio (VD/VT), dyspnea intensity (Borg scale), and exercise time
6.Respiratory muscle pressure (MIP), maximum inspiratory pressure (MIP), minimum expiratory pressure (MEP), |MIP|/MEP
7.Dual-energy X-ray absorptiometry (DEXA)
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
No treatment
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Food | Other |
Interventions/Control_1
1)All patients will be classified into two groups according to the change in Ti/Ttot during CPET. The patients in the Ti/Ttot increased group will receive inspiratory muscle training; the patients will receive inspiratory muscle training 30 times, twice per day for 3 months. The load of the respiratory training will be started at 20% of the maximum inspiratory pressure obtained at baseline and can be increased once every 2 weeks to up to 50% of the maximum pressure.
2)Administration of edible oil that comprises medium-chain C8 (octanoic acid) and C10 (decanoic acid) triglycerides.
<The administration schedule of edible oil>
2.5 g of edible oil that comprises medium-chain C8 and C10 triglycerides will be administered orally, once daily, for 3 months.
Interventions/Control_2
1)All patients will be classified into two groups according to the change in Ti/Ttot during CPET. The patients in the Ti/Ttot decreased group will receive expiratory muscle training; the patients will receive expiratory muscle training 30 times, twice per day for 3 months. The load of the respiratory training will be started at 20% of the maximum expiratory pressure obtained at baseline and can be increased once every 2 weeks to up to 50% of the maximum pressure.
2)Administration of edible oil that comprises medium-chain C8 (octanoic acid) and C10 (decanoic acid) triglycerides.
<The administration schedule of edible oil>
2.5 g of edible oil that comprises medium-chain C8 and C10 triglycerides will be administered orally, once daily, for 3 months.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 40 | years-old | <= |
Age-upper limit
| 85 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1)Patients with moderate to very severe COPD (FEV1% < 70%, and %FEV1 < 80%, mMRC: grade 1and higher)
2)Patients whose conditions are stable and who are able to tolerate cardiopulmonary exercise testing to ensure adequate evaluation
3)Patients who have signed the agreement for participation in this study
Key exclusion criteria
1)Patients with malignant tumors
2)Patients with active infection
3)Patients with severe heart disease
4)Patients with asthma
5)Patients whose drug regimen was changed during this study
6)Patients who receive pulmonary rehabilitation
7)Patients who receive oxygen therapy at rest
8)Patients who are undergoing diabetes mellitus therapy or whose HbA1C is >7.0
9)In addition to the above exclusion criteria, patients judged by their physician to be inadequate to participate in this study
Target sample size
20
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Keisuke Miki |
Organization
National Hospital Organization Toneyama National Hospital
Division name
Department of Respiratory Medicine
Zip code
Address
5-1-1 Toneyama, Toyonaka, Osaka, 560-8552, Japan.
TEL
06-6853-2001
mikisuke@toneyama.go.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Keisuke Miki |
Organization
National Hospital Organization Toneyama National Hospital
Division name
Department of Respiratory Medicine
Zip code
Address
5-1-1 Toneyama, Toyonaka, Osaka, 560-8552, Japan.
TEL
06-6853-2001
Homepage URL
mikisuke@toneyama.go.jp
Sponsor or person
Institute
National Hospital Organization Toneyama National Hospital
Institute
Department
Personal name
Funding Source
Organization
Grant-in-Aid for Clinical Research from National Hospital Organization
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 02 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2018 | Year | 01 | Month | 20 | Day |
Date of IRB
| 2018 | Year | 01 | Month | 19 | Day |
Anticipated trial start date
| 2018 | Year | 02 | Month | 01 | Day |
Last follow-up date
| 2020 | Year | 06 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2018 | Year | 01 | Month | 22 | Day |
Last modified on
| 2022 | Year | 01 | Month | 25 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035288
